Association of Platelet Parameters With Bleeding Severity in Children With ITP
NCT03810352 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 95
Last updated 2024-03-15
Summary
Patients with severe immune thrombocytopenia (ITP) present with similarly low platelet counts but varying bleeding symptoms, making it difficult to predict the disease course and to decide on an appropriate treatment plan. In a single-center study, platelet parameters including the immature platelet fraction, the absolute immature platelet count , and functional response markers were found to be significantly associated with patient bleeding severity, independent of platelet count. This study aims to confirm and replicate these findings in a multi-center patient population and to investigate the use of these parameters to better predict disease severity and bleeding events.
Conditions
Sponsors & Collaborators
-
Sysmex America, Inc.
collaborator INDUSTRY -
Children's Hospital Colorado
collaborator OTHER -
Children's Hospital of Philadelphia
collaborator OTHER -
Baylor College of Medicine
collaborator OTHER - collaborator OTHER
- collaborator OTHER
- lead OTHER
Eligibility
- Min Age
- 6 Months
- Max Age
- 20 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2019-03-15
- Primary Completion
- 2023-11-26
- Completion
- 2023-11-26
Countries
- United States
Study Locations
More Related Trials
-
Safety of Oral Thrombopoietin Receptor Agonist in Pediatric Chronic ITP
NCT05846529 ·Status: UNKNOWN
-
Long-term Study of Romiplostim in Thrombocytopenic Pediatric Patients With Immune Thrombocytopenia (ITP)
NCT02279173 ·Status: COMPLETED ·Phase: PHASE3
-
Long-term Safety Study of Treatment With the Thrombopoietin Agonists Eltrombopag and Romiplostim in Patients With Immune Thrombocytopenia (ITP)
NCT01443351 ·Status: WITHDRAWN
-
Study of Platelets Sialylation by Flow Cytometry for the Differential Diagnosis of ICT
NCT03421392 ·Status: COMPLETED
-
Cohort of Children With Acute Immune or Idiopathic Thrombocytopenic Purpura (ITP) : a Prospective Study in Pays De La Loire
NCT00331357 ·Status: UNKNOWN
-
Eltrombopag in Chronic ITP
NCT04102033 ·Status: UNKNOWN ·Phase: PHASE4
-
Clinical Trial of Rituximab in Children and Adolescents With Chronic Idiopathic Thrombocytopenic Purpura (ITP)
NCT01713738 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
A Study Evaluating the Safety and Efficacy of Long-term Dosing of Romiplostim in Thrombocytopenic Pediatric Patients With Immune (Idiopathic) Thrombocytopenia Purpura
NCT01071954 ·Status: COMPLETED ·Phase: PHASE3
-
An Epidemiological Study of Subjects With Immune Thrombocytopenic Purpura to Evaluate the Relationship Between Platelet Counts, Endogenous Thrombopoietin Levels, Endogenous Anti-Thrombopoietin Antibodies, and Selected Autoimmune Markers
NCT00005570 ·Status: COMPLETED
-
National Multicenter Retrospective Real-World Study on the Treatment Status of Newly Diagnosed and Persistent Primary Immune Thrombocytopenia (ITP) Patients
NCT07268898 ·Status: NOT_YET_RECRUITING
-
Immunomodulation With Romiplostim in Young Adults With ITP
NCT02760251 ·Status: COMPLETED ·Phase: PHASE4
-
Extended Platelet Parameters as a Means to Differentiate Immune Thrombocytopenia From Hypo-proliferative Thrombocytopenias.
NCT01933035 ·Status: COMPLETED
-
A Retrospective Chart Review of Thirty Three Children Who Have Received Clinical Treatment With Either Romiplostim or Eltrombopag From 2009-2013
NCT01974232 ·Status: COMPLETED
-
Steroid Resistance in Pediatric Immune Thrombocytopenic Purpura
NCT06601543 ·Status: NOT_YET_RECRUITING
-
Safety and Efficacy Study of Romiplostim (AMG 531) to Treat ITP in Pediatric Subjects
NCT00515203 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Retrospective & Prospective Observational Study of Patients With Immune (Idiopathic) Thrombocytopenic Purpura (ITP)
NCT00454857 ·Status: COMPLETED
-
Cognitive Status, Fatigue and Inflammation in Patients With Immune Thrombocytopenia (ITP)
NCT06665308 ·Status: COMPLETED
-
Safety and Efficacy Study of Romiplostim to Treat Immune Thrombocytopenia (ITP) in Pediatric Patients
NCT01444417 ·Status: COMPLETED ·Phase: PHASE3
-
Initial Hemato-immunological Profile on the Evolution of Immunological Thrombopenic Purpura.
NCT04070599 ·Status: COMPLETED ·Phase: PHASE3
-
The Association Between Platelet Reactivity and Bleeding Risk in Adult ITP
NCT03377439 ·Status: UNKNOWN
-
Efficacy and Safety Study of Eltrombopag in Pediatric Patients With Thrombocytopenia From Chronic Idiopathic Thrombocytopenic Purpura (ITP)
NCT00908037 ·Status: COMPLETED ·Phase: PHASE2
-
The Outcome of the Thrombopoietin Receptor Agonists in Pediatric Patient With Persistent or Chronic ITP Unresonsive to Steroids
NCT06568913 ·Status: RECRUITING ·Phase: NA
-
Anti-CD38 Antibody Treating Pediatric Primary Immune Thrombocytopenia (ITP)
NCT06168851 ·Status: RECRUITING ·Phase: PHASE2
-
A Study to Investigate Belimumab for the Treatment of Chronic Immune Thrombocytopenia.
NCT01440361 ·Status: WITHDRAWN ·Phase: PHASE2
-
Childhood Reactive Thrombocytosis
NCT01230528 ·Status: COMPLETED